RU2006145829A - Способы прогнозирования терапевтического ответа на агенты, действующие на рецептор гормона роста - Google Patents
Способы прогнозирования терапевтического ответа на агенты, действующие на рецептор гормона роста Download PDFInfo
- Publication number
- RU2006145829A RU2006145829A RU2006145829/14A RU2006145829A RU2006145829A RU 2006145829 A RU2006145829 A RU 2006145829A RU 2006145829/14 A RU2006145829/14 A RU 2006145829/14A RU 2006145829 A RU2006145829 A RU 2006145829A RU 2006145829 A RU2006145829 A RU 2006145829A
- Authority
- RU
- Russia
- Prior art keywords
- specified
- ghr
- agent
- subject
- allele
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Analytical Chemistry (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Obesity (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
Claims (15)
1. Способ прогнозирования ответа субъекта на агент, способный к связыванию с белком рецептора гормона роста (GHR), при котором у субъекта определяют присутствие или отсутствие аллеля GHRd3 и/или аллеля GHRf1 гена GHR, где аллель GHRd3 коррелирует с вероятностью обладания сниженным положительным ответом на указанный агент, а аллель GHRf1 коррелирует с вероятностью обладания повышенным положительным ответом на указанный агент, посредством чего идентифицируют этого субъекта как обладающего сниженной или повышенной вероятностью ответа на лечение указанным агентом.
2. Способ по п.1, где указанный субъект имеет идиопатическую низкорослость (ИНР), очень низкую массу при рождении (ОНМР), внутриматочную задержку роста (ВМ3Р) или является малым для гестационного возраста (МГВ).
3. Способ по п.2, где указанный субъект является МГВ.
4. Способ по любому из пп.1-3, где указанный агент представляет собой агонист GHR.
5. Способ по п.4, где указанный агонист GHR представляет собой гормон роста (GH), предпочтительно соматропин.
6. Способ по п.1, где указанный агент представляет собой антагонист GHR.
7. Способ по п.6, где указанный антагонист GHR представляет собой пегвисомант (pegvisomant).
8. Способ лечения субъекта, страдающего заболеванием или расстройством, в которое вовлечен GHR, при котором (а) определяют у субъекта присутствие или отсутствие аллеля GHRd3 и/или аллеля GHRf1 гена GHR, где аллель GHRd3 коррелирует с вероятностью обладания сниженным положительным ответом на агент, способный к связыванию с белком GHR или действующий через путь GHR, а аллель GHRf1 коррелирует с вероятностью обладания повышенным положительным ответом на указанный агент; и (б) выбирают или определяют эффективное количество указанного агента для введения указанному субъекту.
9. Способ по п.8, где указанный субъект, обладающий низкорослостью, имеет идиопатическую низкорослость (ИНР), очень низкую массу при рождении (ОНМР), внутриматочную задержку роста (ВМ3Р) или является малым для гестационного возраста (МГВ).
10. Способ по п.9, где указанный субъект является МГВ.
11. Способ по п.8, где указанный агент представляет собой агонист GHR.
12. Способ по п.11, где указанный агонист GHR представляет собой GH, предпочтительно соматропин.
13. Способ по п.8, где указанный агент представляет собой антагонист GHR.
14. Способ по п.13, где указанный антагонист GHR представляет собой пегвисомант.
15. Способ по любому из пп.8-14, при котором дополнительно (в) вводят указанное эффективное количество указанного агента указанному субъекту.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58638004P | 2004-07-08 | 2004-07-08 | |
| US60/586,380 | 2004-07-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2006145829A true RU2006145829A (ru) | 2008-08-20 |
Family
ID=34972546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006145829/14A RU2006145829A (ru) | 2004-07-08 | 2005-06-27 | Способы прогнозирования терапевтического ответа на агенты, действующие на рецептор гормона роста |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20080070248A1 (ru) |
| EP (1) | EP1766067A1 (ru) |
| JP (1) | JP2008505634A (ru) |
| KR (1) | KR20070029245A (ru) |
| CN (1) | CN1981056A (ru) |
| AU (1) | AU2005261356A1 (ru) |
| BR (1) | BRPI0512709A (ru) |
| CA (1) | CA2572675A1 (ru) |
| IL (1) | IL180098A0 (ru) |
| MX (1) | MXPA06014924A (ru) |
| NO (1) | NO20065624L (ru) |
| RU (1) | RU2006145829A (ru) |
| TW (1) | TW200617176A (ru) |
| WO (1) | WO2006006072A1 (ru) |
| ZA (1) | ZA200700045B (ru) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5137096B2 (ja) * | 2006-07-05 | 2013-02-06 | 独立行政法人酒類総合研究所 | 特定の麹菌の同定方法 |
| EP2367951B1 (en) * | 2008-11-26 | 2014-06-11 | Merck Serono S.A. | Compositions and methods for treating growth hormone deficiency |
| WO2010135391A2 (en) * | 2009-05-21 | 2010-11-25 | Svetlana Ten | An improved method for diagnosing or predicting short stature in humans |
| EP2670428A1 (en) | 2011-02-01 | 2013-12-11 | Mor Research Applications Ltd. | Use of hgh for the treatment of small for gestational age infants under two years of age |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0300959D0 (sv) * | 2002-12-19 | 2003-04-02 | Pharmacia Ab | Methods for predicting therapeutic response to agents acting on the growth hormone receptor |
-
2005
- 2005-06-27 EP EP05757082A patent/EP1766067A1/en not_active Withdrawn
- 2005-06-27 RU RU2006145829/14A patent/RU2006145829A/ru unknown
- 2005-06-27 KR KR1020077000357A patent/KR20070029245A/ko not_active Application Discontinuation
- 2005-06-27 WO PCT/IB2005/002086 patent/WO2006006072A1/en active Application Filing
- 2005-06-27 CN CNA2005800228888A patent/CN1981056A/zh active Pending
- 2005-06-27 CA CA002572675A patent/CA2572675A1/en not_active Abandoned
- 2005-06-27 AU AU2005261356A patent/AU2005261356A1/en not_active Abandoned
- 2005-06-27 JP JP2007519913A patent/JP2008505634A/ja active Pending
- 2005-06-27 US US11/659,996 patent/US20080070248A1/en not_active Abandoned
- 2005-06-27 MX MXPA06014924A patent/MXPA06014924A/es unknown
- 2005-06-27 BR BRPI0512709-2A patent/BRPI0512709A/pt not_active IP Right Cessation
- 2005-07-07 TW TW094123056A patent/TW200617176A/zh unknown
-
2006
- 2006-12-06 NO NO20065624A patent/NO20065624L/no not_active Application Discontinuation
- 2006-12-14 IL IL180098A patent/IL180098A0/en unknown
-
2007
- 2007-01-02 ZA ZA200700045A patent/ZA200700045B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20080070248A1 (en) | 2008-03-20 |
| NO20065624L (no) | 2007-01-03 |
| EP1766067A1 (en) | 2007-03-28 |
| CN1981056A (zh) | 2007-06-13 |
| CA2572675A1 (en) | 2006-01-19 |
| AU2005261356A1 (en) | 2006-01-19 |
| IL180098A0 (en) | 2007-05-15 |
| ZA200700045B (en) | 2008-06-25 |
| KR20070029245A (ko) | 2007-03-13 |
| MXPA06014924A (es) | 2007-02-28 |
| BRPI0512709A (pt) | 2008-04-01 |
| JP2008505634A (ja) | 2008-02-28 |
| WO2006006072A1 (en) | 2006-01-19 |
| TW200617176A (en) | 2006-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kapoor et al. | Fetal programming of hypothalamo‐pituitary‐adrenal function: prenatal stress and glucocorticoids | |
| Gajdos et al. | What controls the timing of puberty? An update on progress from genetic investigation | |
| Carini et al. | Effects of early life social stress on endocrinology, maternal behavior, and lactation in rats | |
| Huang et al. | The Ser680Asn polymorphism in the follicle‐stimulating hormone receptor gene is associated with the ovarian response in controlled ovarian hyperstimulation | |
| Leniger et al. | A new Chrna4 mutation with low penetrance in nocturnal frontal lobe epilepsy | |
| Hochberg | Evo-devo of child growth: treatise on child growth and human evolution | |
| Oliveira et al. | Peripheral mechanisms underlying the essential role of P2X3, 2/3 receptors in the development of inflammatory hyperalgesia | |
| Tuchscherer et al. | Effects of postnatal social isolation on hormonal and immune responses of pigs to an acute endotoxin challenge | |
| Merhi et al. | Male adiposity impairs clinical pregnancy rate by in vitro fertilization without affecting day 3 embryo quality | |
| RU2006145829A (ru) | Способы прогнозирования терапевтического ответа на агенты, действующие на рецептор гормона роста | |
| León et al. | Tachykinin signaling is required for induction of the preovulatory luteinizing hormone surge and normal luteinizing hormone pulses | |
| Úbeda et al. | Ecology drives intragenomic conflict over menopause | |
| Robeva et al. | Androgen receptor (CAG) n polymorphism and androgen levels in women with systemic lupus erythematosus and healthy controls | |
| Soeterik et al. | Electroejaculation in psychogenic anejaculation | |
| Winnicki et al. | alpha-Adducin Gly460Trp polymorphism, left ventricular mass and plasma renin activity | |
| Akkaya et al. | A single-nucleotide polymorphism in a Plasmodium berghei ApiAP2 transcription factor alters the development of host immunity | |
| Liu et al. | Gene expression profiles of intracellular and membrane progesterone receptor isoforms in the mediobasal hypothalamus during pro‐oestrus | |
| Brunetta et al. | Omalizumab for idiopathic nonhistaminergic angioedema: evidence for efficacy in 2 patients | |
| Mantei et al. | Courtship interactions stimulate rapid changes in GnRH synthesis in male ring doves | |
| CA2601600A1 (en) | Substituted aryl 1,4-pyrazine derivatives | |
| Sam et al. | Inherited neurovascular diseases affecting cerebral blood vessels and smooth muscle | |
| Foresta et al. | Follicle-stimulating hormone treatment of male infertility | |
| Södersten et al. | Psychoneuroendocrinology of anorexia nervosa | |
| SE0300959D0 (sv) | Methods for predicting therapeutic response to agents acting on the growth hormone receptor | |
| Frattarelli et al. | Clinical impact of LH rises prior to and during ganirelix treatment started on day 5 or on day 6 of ovarian stimulation |